

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

204427Orig1s000

SUMMARY REVIEW

Summary Review for Regulatory Action

Date	(electronic stamp)
From	Tatiana Oussova, M.D., M.P.H.
Subject	Deputy Division Director for Safety Summary Review
NDA/BLA #	NDA 204427
Supplement #	
Applicant Name	Anacor Pharmaceuticals, Inc.
Date of Submission	July 29, 2013
PDUFA Goal Date	July 29, 2014
Proprietary Name / Established (USAN) Name	Kerydin (tavaborole)
Dosage Forms / Strength	Topical solution 5%
Proposed Indication(s)	Treatment of onychomycosis of the toenail due to <i>Trichophyton rubrum</i> or <i>Trichophyton mentagrophytes</i>
Action/Recommended Action for NME:	Approval

Material Reviewed/Consulted	Names of discipline reviewers
OND Action Package, including:	
Medical Officer Review	Milena Lolic, M.D.
Statistical Review	Kathy Fritsch, Ph.D.
Pharmacology Toxicology Review	Barbara Hill, Ph.D.
CMC Review/OBP Review	Gene W. Holbert, Ph.D.
Microbiology Review	Kerian Grande Roche, Ph.D.
Clinical Pharmacology Review	Angela Lu, Ph.D.
DDMAC	
OSI	Roy Blay, Ph.D.
CDTL Review	David Kettl, M.D.
OSE/DMEPA	Carlos M Mena-Grillasca, RPh
OSE/DDRE	
OSE/DRISK	Nyedra W. Booker, Pharm.D., M.P.H.
CDTL Review	David Kettl, M.D.

OND=Office of New Drugs
DDMAC=Division of Drug Marketing, Advertising and Communication
OSE= Office of Surveillance and Epidemiology
DMEPA=Division of Medication Error Prevention and Analysis
OSI=Office of Scientific Investigations
DDRE= Division of Drug Risk Evaluation
DRISK=Division of Risk Management
CDTL=Cross-Discipline Team Leader

Signatory Authority Review Template

1. Introduction

This is a 505 (b)(1) new drug application for a new molecular entity (NME), tavaborole, submitted by Anacor Pharmaceuticals, Inc. for the proposed indication: “ the treatment of onychomycosis [REDACTED] (b)(4) However, the data submitted support [REDACTED] (b)(4) indication: “ the treatment of toenail onychomycosis caused by *Trichophyton rubrum* or *Trichophyton mentagrophytes*”. This application has been reviewed under the PDUFA V Program.

Tavaborole is an oxaborole, the first in a new class of antifungal agents. It is a topical solution for an application to an affected toenail.

There was a recent approval (June 2014) of another topical antifungal product Jublia (eficonazole) for a similar indication. However, prior to that the last approval of a topical product for the treatment of onychomycosis of a toenail was issued to Penlac (ciclopirox) in 1999.

Tavaborole has not been approved in any other countries.

The Applicant proposed proprietary name KERYDIN was found acceptable.

There are no outstanding clinical or regulatory concerns. All discipline reviews have been completed and approval is recommended. There were no disagreements within the review team. There were a few disagreements between the Applicant and the review team on labeling issues that have been resolved. This review will provide more details on those issues and will briefly summarize the review team conclusions and my concurrence with the approval recommendation.

2. Background

The Applicant opened an IND for tavaborole in 2005 with a pharmacokinetic study. Since then, the Agency had multiple interactions with the Applicant, including EOP2 meeting in 2009, Guidance Meeting in 2012 and pre-NDA meeting in May of 2013.

Request for a special protocol assessment (SPA) was received on August 4, 2010 and the Agreement Letter was sent to the Applicant on September 13, 2010. Pivotal clinical studies were conducted according to the agreement.

Onychomycosis is a chronic fungal infection of toenails and/or fingernails. It is estimated that 15-20% of persons in United States between 40 and 60 years old have onychomycosis. It is more prevalent in adults than in children (prevalence rate 0.2% to 2.6%). The most common site of infection is the toenail. The most common type of toenail onychomycosis is distal subungual onychomycosis and the most common dermatophytes causing distal subungual onychomycosis are *Trichophyton rubrum* and *Trichophyton mentagrophytes*. Fingernail onychomycosis is more likely to be caused by yeasts, most commonly *Candida albicans*.

The clinical manifestations of onychomycosis include separation of the nail plate from the nail bed (onycholysis), subungual hyperkeratosis, and changes in the nail plate that make it thicker, brittle, and discolored. Symptoms include toenail discomfort when walking, pain and social embarrassment.

Without treatment, the disease can cause progressive damage to the nail unit, and can spread to infect other nails, the skin, or potentially predispose to secondary bacterial infections (in immunocompromised populations). The criteria for diagnosis of onychomycosis include clinical evaluation, potassium hydroxide (KOH) microscopic evaluation, and fungal culture.

The mechanism of action of tavaborole is inhibition of fungal protein synthesis. Tavaborole inhibits protein synthesis by inhibition of an aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS). Tavaborole has been shown to be active against most strains of *Trichophyton mentagrophytes* and *Trichophyton rubrum*.

Tavaborole should be applied to the entire nail surface and under the tip of each nail being treated once daily for 48 weeks.

3. CMC/Device

KERYDIN topical solution, 5% is an alcohol/propylene glycol based clear, colorless solution containing 5% tavaborole (w/w).

The product is packaged with a (b)(4) dropper assembly, which is used to apply the product to the affected nail. The dropper assembly consists of a clear glass straight-tip pipette fitted with a rubber squeeze bulb and a black (b)(4) closure.

The proposed drug product specification includes tests and acceptance criteria for the following attributes: description, identity, tavaborole assay, impurities, EDTA assay, packaging integrity, weight loss, minimum fill, and microbiological testing.

I concur with the conclusions reached by the chemistry reviewer regarding the acceptability of the manufacturing of the drug product and drug substance. Manufacturing site inspections were acceptable. The stability data support the proposed expiration dating period of 24 months for tavaborole solution when stored at 20-25 °C (68-77 °F).

The product is flammable and it is reflected in the label.

There are no outstanding issues.

4. Nonclinical Pharmacology/Toxicology

The non-clinical pharmacology/toxicology data for this application was reviewed by Barbara Hill, Ph.D. Dr. Hill concluded that “the toxicity profile of tavaborole solution has been well characterized by the nonclinical studies conducted by the sponsor. There is no significant

safety concern for tavaborole solution at the proposed clinical dose". The most notable adverse effect was dose-dependent dermal irritation at the application site.

Dr. Hill recommended approval for this application.

I concur with the conclusions reached by the pharmacology/toxicology reviewer that there are no outstanding pharm/tox issues that preclude approval.

5. Clinical Pharmacology/Biopharmaceutics

The clinical pharmacology data was reviewed by An Chi Lu, Ph.D. PK data was assessed in maximal use study of 24 subjects with toenail onychomycosis. Tavaborole undergoes extensive metabolism and renal excretion is the major route of elimination. No formal drug-drug interaction studies were conducted. In vitro studies and induction studies indicated that tavaborole is not likely to induce the activity of CYP450 enzymes.

The Applicant proposed [REDACTED] (b) (4) Section 12.1, Mechanism of Action. Both Clinical and PK teams disagree with this proposal. In clinical trials the product was applied onto entire nail surface including under the tip of the nail therefore the clinical effect is due to penetration of the drug through different structures, [REDACTED] (b) (4). The Applicant has agreed to this rationale.

The Applicant did not conduct PK studies in pediatric population therefore the PREA PMR will be issued with the approval letter requiring the Applicant to conduct maximal use study in pediatric patients ages 12 to 17 year 11 months with onychomycosis of toenails. Dr. Lu recommended approval for this application.

I concur with the conclusions reached by the clinical pharmacology/biopharmaceutics reviewer that there are no outstanding clinical pharmacology issues that preclude approval.

6. Clinical Microbiology

Clinical microbiology review was conducted by Kerian Grande Roche, Ph.D.

This review was critical for this application as the Applicant proposed a [REDACTED] (b) (4) for the treatment of onychomycosis [REDACTED] (b) (4). Mycological testing (fungal culture and KOH wet mount) was performed in five Phase 2 and two Phase 3 studies of subjects with onychomycosis.

The microbiology studies included examination of the spectra of activity of tavaborole and characterization of the mycology and susceptibility of strains of *Trichophyton rubrum* and *Trichophyton mentagrophytes*, obtained from clinical isolates of subjects treated with tavaborole topical solution, 5% for 48 weeks. Tavaborole has been shown to be active against most strains of *Trichophyton mentagrophytes* and *Trichophyton rubrum*, both in vitro and in clinical infections. Given that clinical development program only evaluated subjects with toenail onychomycosis plus supporting data from microbiology testing, only data for toenail

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.